A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate
the safety of different doses and dosing regimens of oral rucaparib administered daily to
patients with solid tumors.
Part 2A (Completed Enrollment) and Part 2B (Completed Enrollment) - The purpose of the second
part of the study is to determine the safety and clinical activity of the RP2D of oral
rucaparib administered daily to patients with a known deleterious BRCA mutation (germline or
somatic).
Part 3 (Completed Enrollment) - The purpose of the third part of the study is to further
evaluate PK of higher dose strength tablets at the RP2D in patients with any advanced solid
tumor, inclusive of lymphoma, with evidence of a BRCA mutation (germline or somatic).